The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Frauwirth, K. A.
Right arrow Articles by Thompson, C. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Frauwirth, K. A.
Right arrow Articles by Thompson, C. B.
The Journal of Immunology, 2000, 164: 2987-2993.
Copyright © 2000 by The American Association of Immunologists

Induction of T Cell Anergy in the Absence of CTLA-4/B7 Interaction1

Kenneth A. Frauwirth*, Maria-Luisa Alegre{dagger} and Craig B. Thompson2,*

* Abramson Family Cancer Research Institute and Department of Cancer Biology, University of Pennsylvania, Philadelphia, PA 19104; and {dagger} Department of Medicine, University of Chicago, Chicago, IL 60637


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Immunologic tolerance in T lymphocytes is maintained through both thymic and peripheral contributions. One peripheral tolerance mechanism is the induction of T cell anergy, a form of nonresponsiveness resulting from incomplete T cell activation, such as stimulation through the TCR in the absence of costimulation. Recent reports have suggested that engagement of the inhibitory receptor CTLA-4 by its B7 ligand is critical for the initiation of anergy. We tested the importance of CTLA-4 in anergy induction in primary T cells with an in vitro anergy system. Using both CTLA-4/B7-blocking agents and CTLA-4-deficient T cells, we found that T cell anergy can be established in the absence of CTLA-4 expression and/or function. Even in the absence of CTLA-4 signal transduction, T cells activated solely through TCR ligation lose the ability to proliferate as a result of autocrine IL-2 production upon subsequent receptor engagement. Thus, CTLA-4 signaling is not required for the development of T cell anergy.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
The activation of resting T lymphocytes is a highly regulated process requiring two distinct signaling events. Upon interaction of the TCR with its cognate peptide/MHC complex on an APC, signal 1 is initiated by the TCR-associated CD3 complex. However, full activation does not occur unless a second, costimulatory signal (signal 2) is also received. An important costimulatory molecule on resting T cells appears to be CD28 (1, 2, 3), which initiates signaling after binding to members of the B7 family on the APC; however, other T cell surface molecules, such as CD2 (4), LFA-1 (5, 6, 7), and CD27 (8), have been reported to have costimulatory activity.

T cells that receive signal 1 in the absence of signal 2 enter a state of nonresponsiveness to subsequent stimulation (9, 10, 11). This nonresponsiveness, termed anergy, is characterized by a failure to proliferate or secrete IL-2 upon Ag receptor engagement even in the presence of costimulation. Anergic T cells have been reported to have defects in the Ras and mitogen-activated protein kinase signaling pathways (12, 13, 14), reduced Ca2+ flux (15), and altered tyrosine kinase activity (15, 16). These signaling deficiencies appear to lead to reduced NF-{kappa}B and AP-1 transcriptional activities (17, 18, 19). Anergy was originally described in CD4+ T cell clones, but it has since been shown to occur in primary CD4+ and CD8+ T cells, both in vitro and in vivo (20, 21, 22, 23, 24), and may be a significant component of peripheral tolerance.

Several groups have recently proposed that CTLA-4, a molecule expressed on activated T cells, acts as the trigger for anergy (20, 21). CTLA-4, like CD28, binds to members of the B7 family, but has an inhibitory effect on T cell activation (25, 26), making CTLA-4 a logical candidate for initiating anergy. Further, the defects in anergic cells appear to be similar to the acute effects of CTLA-4 cross-linking, namely blockade of proliferation and IL-2 production (25, 26), reduction of mitogen-activated protein kinase activation (27, 28), and inhibition of AP-1 and NF-{kappa}B activity (29). Indeed, administration of anti-CTLA-4 blocking Abs during anergy induction appears to inhibit the induction of T cell hyporesponsiveness in several systems (20, 21, 30, 31, 32), and these observations are the basis for models invoking CTLA-4 signal transduction in the induction of anergy.

Although the hypothesis that CTLA-4 is the anergy initiator molecule is an attractive one, many in vitro anergy systems exclude B7.1/2-expressing APC, and B7.1/2-blocking agents have been used to induce anergy when B7-expressing cells are present (33, 34, 35, 36, 37, 38). Because interaction with B7 is required for CTLA-4 signaling, it is difficult to reconcile the model with these data. We therefore undertook a direct examination of the role of CTLA-4 in the initiation of T cell anergy. Using both reagents that block the CTLA-4/B7 interaction and CTLA-4-deficient T cells, we found that CTLA-4 signaling is not required for anergy induction in vitro.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Animals

Female C57BL/6 mice (4–8 wk old) were purchased from The Jackson Laboratory (Bar Harbor, ME). Lck-Bcl-xL transgenic mice have been described previously (39). F5 TCR transgenic (40)/recombination-activating gene 1 (RAG1-/-)3/CTLA-4+/- mice were provided by Dr. Philip Ashton-Rickardt (University of Chicago, Chicago, IL). 2C TCR transgenic (41)/RAG2-/-/CTLA-4+/- mice were provided by Dr. Thomas Gajewski (University of Chicago). DO.11.10 TCR transgenic mice (42) were the gift of Dr. Kenneth Murphy (Washington University, St. Louis, MO). All mice were maintained in the University of Chicago Animal Barrier Facilities.

Abs and reagents

UC10-4F10-11 (4F10; hamster anti-CTLA-4) and 145-2C11 (2C11; hamster anti-CD3{epsilon}) were purified from hybridoma supernatants by passage over protein A-Sepharose columns. FITC-labeled hamster IgG, anti-Thy1.2, anti-CD3, anti-TCR, anti-CD25, PE-labeled hamster IgG, anti-Thy1.2, anti-CD69, anti-CD44, and anti-CD62L were purchased from PharMingen (San Diego, CA). Murine CTLA4-Ig was provided by Genetics Institute (Cambridge, MA). Influenza nucleoprotein 366–374 peptide ASNENMDAM (H-2Db restricted, F5 TCR reactive) was provided by Dr. Philip Ashton-Rickardt (University of Chicago). The H-2Kb-restricted 2C TCR-reactive peptide SIYRYYGL and the OVA323–339 peptide ISQAVHAAHAEINEAGR (I-Ad restricted, DO.11.10 TCR reactive) were purchased from Multiple Peptide Systems (San Diego, CA).

Cell lines and culture

The OVA323–339/I-Ad-specific TH1 clone pGL10 was the gift of Dr. Thomas Gajewski (University of Chicago). All cells were maintained in DMEM (Life Technologies, Grand Island, NY) supplemented with L-glutamine, penicillin, streptomycin, HEPES buffer, MEM nonessential amino acids, 2-ME, and 10% FBS (Life Technologies), at 37°C in a 7% CO2 atmosphere.

T cell purification

Murine T cells were isolated from spleen and mesenteric lymph nodes using the StemSep negative selection system (StemCell Technologies, Vancouver, Canada) following the manufacturer’s instructions. Briefly, single-cell suspensions were prepared by manual disruption of spleen and lymph nodes and passage of cells through nylon mesh. Erythrocytes were depleted by hypotonic lysis. The cells were washed and resuspended in PBS supplemented with 2% FBS and 5% heat-inactivated normal rat serum (Jackson ImmunoResearch Laboratories, West Grove, PA). The cells were incubated with StemSep T cell enrichment Ab cocktail (a mixture of biotinylated anti-B cell, anti-erythrocyte, and anti-myeloid Abs) at 4°C, washed, and resuspended in PBS plus 2% FBS. The cells were then incubated with StemSep anti-biotin tetramer (a bifunctional, anti-biotin/anti-dextran tetramer), followed by incubation with dextran-linked magnetic beads and passage over magnetized columns to deplete non-T cells. The nonretained fraction typically contained >95% Thy1+ cells, as determined by flow cytometry. To purify CD4+ or CD8+ T cells, the appropriate StemSep Ab cocktails (containing the components of the T cell enrichment Ab cocktail plus either anti-CD8 or anti-CD4 Abs, respectively) were used in place of StemSep T cell enrichment Ab cocktail.

In vitro anergy induction

Purified murine T cells were cultured on immobilized anti-CD3 mAb (2C11) for 2 days in the presence or absence of either 50 µg/ml soluble CTLA4-Ig or 25 µg/ml soluble anti-CTLA-4 mAb (4F10). Cells were harvested, resuspended in fresh medium, and cultured for 2 additional days in the absence of anti-CD3 mAb ("rest"). T cells were collected, counted, and tested for anergy by measuring cytokine secretion and proliferation upon restimulation with irradiated C57BL/6 splenocytes and titrated doses of anti-CD3 mAb. For proliferation assays, 5 x 104 T cells plus 2 x 105 splenocytes were cocultured in a final volume of 200 µl. For cytokine assays, 2.5 x 105 T cells plus 1 x 106 splenocytes were cocultured in a final volume of 1 ml. In some experiments with TCR transgenic T cells, the specific peptide was used instead of anti-CD3 mAb in the restimulation cultures.

Cytokine and proliferation assays

IL-2, IL-4, and IFN-{gamma} levels in 1-day restimulation culture supernatants were measured by sandwich ELISA. Primary and biotinylated secondary anti-cytokine Abs were purchased from PharMingen and used at the concentrations recommended by the manufacturer. Alkaline phosphatase-conjugated avidin was purchased from Jackson ImmunoResearch Laboratories and used at a 1/3000 dilution. Colorimetric alkaline phosphatase substrate (Sigma, St. Louis, MO) was used at 1 mg/ml in 10% diethanolamine buffer, and quantitation was performed on a SpectraMax 190 spectrophotometer (Molecular Devices, Sunnyvale, CA). Data were analyzed using SoftMax Pro software (Molecular Devices) by comparison with a standard curve generated using recombinant cytokines at known concentrations. Proliferation after 3 days of restimulation was determined by [3H]thymidine incorporation. Cells were pulsed for 7–8 h with 1 µCi of [3H]thymidine (ICN, Costa Mesa, CA)/well, transferred to glass-fiber filters with a 96-well cell harvester (Tomtec, Hamden, CT), and analyzed by liquid scintillation using a 1205 Betaplate scintillation counter (Wallac, Turku, Finland). Data points for all analyses are presented as the mean of triplicate wells.

Flow cytometry

Levels of CD3, TCR, CD25, CD69, CD44, and CD62L were determined on freshly purified, anti-CD3-treated, and rested T cells by two-color flow cytometry. Following harvest, cells were washed once in FACS buffer (1% BSA and 0.01% sodium azide in PBS, pH 7.4) and incubated for 30 min on ice in 100 µl of FACS buffer containing FITC-conjugated (anti-CD3, anti-TCR, anti-CD25 mAbs) or PE-conjugated (anti-CD69, anti-CD44, anti-CD62L mAbs) mAb; FITC- and PE-conjugated hamster IgG were used as negative controls. Cells were simultaneously stained with PE- or FITC-conjugated anti-Thy1.2 mAb to assess T cell purity. After a final wash, cells were resuspended in FACS buffer and analyzed on a FACSsort flow cytometer (Becton Dickinson, Mountain View, CA). Forward and side scatter gates were used to exclude dead cells. Data from ~104 live cells were analyzed using CellQuest software (Becton Dickinson). For cell cycle analysis, 106 cells were fixed in 25% PBS/75% ethanol for 1 h at 4°C. The fixed cells were resuspended in propidium iodide staining solution (3.8 mM sodium citrate, 0.125 mg/ml RNase A, and 0.01 mg/ml propidium iodide), incubated on ice for 30 min, and then analyzed by flow cytometry as described above.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Induction of anergy in primary T cells in vitro

Many of the studies used to define T cell anergy have been performed using T cell clones. To determine whether anergy could also be established in normal mouse T cells, an anergy induction system using immobilized anti-CD3 Ab (mAb 2C11) to stimulate primary T cells was developed, based on the protocol of Jenkins et al. (10). Culturing purified C57BL/6 T cells on anti-CD3-mAb-coated dishes for 2 days followed by 2 days of rest (culture in the absence of Ab) resulted in a profound nonresponsiveness to restimulation through Ag receptor. The T cells failed to proliferate or secrete IL-2 when stimulated with splenic APC plus anti-CD3 mAb (Fig. 1Go), but were hyper-responsive to exogenously added IL-2 (data not shown), indicating that the lack of response was not due to T cell death during the restimulation. This was confirmed by manual cell count (data not shown).



View larger version (22K):
[in this window]
[in a new window]
  		FIGURE 1. Immobilized anti-CD3 mAb anergizes primary T cells. Splenic T cells were purified from normal C57BL/6 (a and c) or Bcl-xL transgenic (b and c) mice, cultured for 2 days in dishes coated with 10 µg/ml of anti-CD3 mAb 2C11, and then rested for 2 days in fresh medium in uncoated dishes. To assay proliferation (a and b), cells were restimulated for 3 days with irradiated C57BL/6 splenocytes plus titrated soluble mAb 2C11, and incorporation of [3H]thymidine was measured as described in Materials and Methods. IL-2 secretion (c) was determined by ELISA of culture supernatants after 21 h of restimulation with irradiated splenocytes plus 10 µg/ml of soluble mAb 2C11. Proliferation and IL-2 production were compared with those of freshly isolated (untreated) T cells (open symbols/hatched bars). Data are representative of two independent experiments for wild-type C57BL/6 cells and >10 independent experiments for Bcl-xL transgenic cells. Error bars represent 1 SD from the mean of triplicate wells.

 
A major fate of purified T cells was to undergo apoptotic death during the initial 4-day culture, however, limiting the yields of viable anergic cells. This difficulty in maintaining cell survival was not limited to the anergic cell population, as freshly isolated T cells cultured in the absence of stimulation also displayed low levels of viability after 4 days (data not shown). To avoid these obstacles, T cells isolated from animals bearing a transgene for the anti-apoptotic protein Bcl-xL under the control of the Lck proximal promoter (39) were used. The Bcl-xL transgenic (Tg) T cells maintained high viability in culture with or without anti-CD3 mAb stimulation (39) and, like their nontransgenic counterparts, became anergic when treated with immobilized anti-CD3 mAb (Fig. 1Go, b and c). Bcl-xL Tg T cells left untreated in culture for 4 days generally had proliferative and cytokine responses comparable to those of freshly isolated T cells, indicating that the culture conditions themselves did not contribute significantly to nonresponsiveness (data not shown).

During anergy induction, the T cells were induced to express several activation markers, including CD25 (Fig. 2Goa) and CD69 (data not shown), both of which dropped back to near initial levels during the rest period. Culture with anti-CD3 mAb caused a marked reduction in surface CD3 levels, but CD3 was re-expressed to nearly starting levels by the end of the rest period (Fig. 2Gob). T cells also went through blastogenesis during anergy induction (Fig. 3Go).



View larger version (23K):
[in this window]
[in a new window]
  		FIGURE 2. CD25 and CD3 levels on T cells during anergy induction. T cells were stained with FITC-conjugated anti-CD25 mAb (a) or anti-CD3 mAb (b) after purification (untreated), culture on immobilized mAb 2C11 (2 days Ab), and rest culture (2 days rest), and CD25 and CD3 levels were measured by flow cytometry. For CD3, staining with FITC-conjugated hamster IgG (isotype control) is also shown (b). Fluorescence intensity (arbitrary units) is shown on the horizontal axis, and cell number is given on the vertical axis.

 


View larger version (44K):
[in this window]
[in a new window]
  		FIGURE 3. Anergized cells enter cell cycle, but arrest in G1 phase upon restimulation. Purified Bcl-xL transgenic T cells were cultured in medium alone for 4 days (upper panels) or were subjected to anergy induction culture of 2 days on immobilized mAb 2C11 plus 2 days of rest (lower panels) and then stimulated for 3 days with irradiated C57BL/6 splenocytes plus 10 µg/ml of soluble mAb 2C11. Dead T cells and splenocytes were removed by centrifugation over Ficoll, and recovered cells (>95% Th1.2+; not shown) were fixed, stained with propidium iodide, and analyzed for DNA content by flow cytometry after 2 days of primary culture (left panels) and 3 days of restimulation (right panels). Fluorescence intensity is shown on the vertical axis, and forward scatter is shown on the horizontal axis.

 
Several reports have linked anergy induction with G1 arrest (43, 44, 45). The DNA content of T cells was therefore analyzed over the course of anergy induction. Treatment with immobilized anti-CD3 mAb induced progression through S and G2/M phases (Fig. 3Go), and cells returned to G1 phase during the rest period. Upon restimulation, however, the anergized T cells were unable to exit the G1 phase of the cell cycle, unlike T cells that had been left untreated in culture for 4 days (Fig. 3Go). These findings are consistent with results from other models, in which anergy is preceded by an initial proliferative response (21, 46, 47, 48).

Blocking CTLA-4/B7 does not prevent anergy induction

The T cell inhibitory receptor CTLA-4 is thought to be important for the induction and/or maintenance of peripheral tolerance (20, 21, 30, 31, 32, 49, 50, 51). We therefore used the immobilized anti-CD3 mAb/Bcl-xL Tg T cell system to investigate the role of CTLA-4/B7 interactions in anergy induction. Freshly isolated T cells (>95% Thy1+ after purification) did not express detectable B7.1 or B7.2, but up-regulated both B7.2 (transiently) and B7.1 during anti-CD3 mAb treatment (data not shown), raising the possibility that B7 molecules on the T cells themselves could act as the ligands for CTLA-4. We therefore added either CTLA4-Ig, which binds B7 molecules with high affinity, or {alpha}-CTLA-4 mAb (mAb 4F10) to prevent any potential CTLA-4/B7 interactions. Addition of CTLA4-Ig to cultures was completely ineffective at preventing nonresponsiveness (Fig. 4Go, a and b), even at levels that totally abrogated CD28 costimulation in parallel cultures (Fig. 4Goc). Likewise, coculture with soluble {alpha}-CTLA-4 mAb consistently had no appreciable effect on anergy induction (Fig. 5Go).



View larger version (19K):
[in this window]
[in a new window]
  		FIGURE 4. Blockade of CTLA-4/B7 interactions with CTLA4-Ig does not prevent anergy induction. Purified Bcl-xL transgenic T cells were cultured on immobilized mAb 2C11 in the absence (anti-CD3) or the presence (anti-CD3/CTLA4-Ig) of 50 µg/ml of soluble CTLA4-Ig, rested, and restimulated as described. Proliferation (a) and IL-2 secretion (b) were measured as in Fig. 1Go and compared with responses of freshly isolated (untreated) cells. Data are representative of three independent experiments. Error bars represent 1 SD from the mean of triplicate wells. c, CTLA4-Ig activity was confirmed by inhibition of CD28-dependent proliferation. Freshly purified T cells were stimulated with irradiated splenocytes plus soluble mAb 2C11 in the absence (untreated) or the presence of 50 µ/ml of soluble CTLA4-Ig, and proliferation was measured as described in Fig. 1Go.

 


View larger version (24K):
[in this window]
[in a new window]
  		FIGURE 5. Blockade of CTLA-4/B7 interactions with anti-CTLA-4 mAb does not prevent anergy induction. Purified Bcl-xL transgenic T cells were cultured on immobilized mAb 2C11 in the absence (anti-CD3) or the presence (anti-CD3/anti-CTLA-4) of 25 µg/ml of soluble mAb 4F10, rested, and restimulated as described. Proliferation (a) and IL-2 secretion (b) were measured as described in Fig. 1Go. Data are representative of four independent experiments. Error bars represent 1 SD from the mean of triplicate wells.

 
Analysis of CD4+/CD8+ subsets after anergy induction in some experiments revealed a skewing toward CD8+ cells, although the reasons for this are unknown. The reports linking CTLA-4 to anergy either evaluated only CD4+ cells (20) or concluded that {alpha}-CTLA-4 treatment most dramatically affected CD4+ cells (21), raising the concern that our failure to prevent anergy by CTLA-4 blockade might be due at least in part to this CD8+ skewing. We therefore compared anergy induction in purified CD4+ and CD8+ T cells. Culture on immobilized anti-CD3 mAb inhibited subsequent proliferative and IL-2 responses of both subsets, and treatment with {alpha}-CTLA-4 mAb was unable to prevent anergy in either CD4+ (Fig. 6Go) or CD8+ (data not shown) cells. Likewise, CTLA4-Ig did not block induction of anergy in T cells purified from DO.11.10 TCR (OVA/I-Ad-specific) transgenic mice, and neither CTLA4-Ig nor anti-CTLA-4 mAb inhibited anergy induction in the OVA/I-Ad-specific CD4+ clone pGL10 (data not shown).



View larger version (22K):
[in this window]
[in a new window]
  		FIGURE 6. CD4+ T cells can be anergized in the presence of anti-CTLA-4 mAb. CD4+ T cells were purified from Bcl-xL transgenic mice and treated as described in Fig. 6Go, except that neglected cells (T cells cultured in medium alone for 4 days) were used instead of freshly isolated cells for comparison. a, Proliferation. b, IL-2 secretion. Data are representative of two independent experiments. Error bars represent 1 SD from the mean of triplicate wells.

 
CTLA-4-deficient T cells can be anergized

The inability of either CTLA4-Ig or {alpha}-CTLA-4 mAb to prevent T cell nonresponsiveness in this system strongly suggested that CTLA-4 is not required for anergy induction; however, it was possible that neither reagent completely blocked CTLA-4/B7 interactions, allowing a small, but sufficient, amount of CTLA-4 signaling to occur. We therefore made use of CTLA-4-deficient T cells to address this concern. CTLA-4 knockout mice develop a fatal lymphoproliferative disease within 3–4 wk of birth (49, 50). However, when the CTLA-4 deficiency was bred onto TCR transgenic, RAG-/- mice, the exclusive expression of either the 2C (Ld-alloreactive (41)) or F5 (Db/influenza nucleoprotein-reactive (40)) receptor led to T cell populations that avoided the lymphoproliferative disease (M. Alegre, unpublished observations).

To study anergy in the complete absence of CTLA-4, we purified 2C TCR Tg T cells from CTLA-4+ and CTLA-4- age-matched mice and cultured them with immobilized anti-CD3 mAb as described above. As shown in Fig. 7Go, both proliferation and IL-2 secretion were greatly reduced upon restimulation in CTLA-4+ and CTLA-4- T cells after culture on plate-bound anti-CD3 mAb. Although the CTLA-4- cells consistently gave higher overall responses, the degree of inhibition by the anergizing treatment was comparable (IL-2 secretion: ~84% inhibition with CTLA-4+ cells, ~79% with CTLA-4- cells; proliferation: ~94% inhibition with CTLA-4+ cells, ~89% with CTLA-4- cells; averaged over the top three peptide concentrations). Treatment with immobilized anti-CD3 mAb also inhibited subsequent proliferative responses equally in CTLA-4+ and CTLA-4- F5 TCR Tg T cells (Fig. 7Goc).



View larger version (22K):
[in this window]
[in a new window]
  		FIGURE 7. CTLA-4-deficient TCR Tg T cells can be anergized in vitro. a and b, T cells were purified from 2C TCR Tg/RAG2-/CTLA-4+/+ (filled symbols) or CTLA-4-/- (open symbols) mice and stimulated with antigenic peptide and irradiated C57BL/6 splenocytes without (untreated) or after (anti-CD3) culture on immobilized mAb 2C11. Proliferation (a) and IL-2 levels (b) were measured as described in Fig. 1Go. c, T cells were purified from F5 TCR Tg/RAG1-/CTLA-4+/- (filled symbols) or CTLA-4-/- (open symbols) mice and stimulated with or without prior culture on immobilized anti-CD3 mAb as described in a, except that soluble mAb 2C11 was used in place of antigenic peptide for the stimulation. Data are representative of three independent experiments for 2C T cells and two independent experiments for F5 T cells. Error bars represent 1 SD from the mean of triplicate wells.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
To study anergy in primary T cells, we established an in vitro system using immobilized anti-CD3 mAb as the anergizing agent. We found that induction of anergy follows an activation phase, which includes expression of CD25 and CD69, modulation of CD3, blastogenesis, and progression through the cell cycle. We further demonstrated that anergy can be induced in primary T cells in the absence of any CTLA-4/B7 interaction. Neither CTLA4-Ig nor {alpha}-CTLA-4 mAb was able to prevent anergy induced by immobilized anti-CD3 mAb, and CTLA-4-deficient T cells were as susceptible as CTLA-4-expressing cells to anergy induction. Thus, CTLA-4 is not required for initiating T cell anergy in this system.

These results conflict with reports from the Abbas (20) and Bluestone (21) groups, which identified CTLA-4 as critical for anergy induction. One explanation for this discrepancy may be our use of an in vitro system. Perez et al. analyzed anergy induced in vivo by soluble Ag, and Walunas et al. studied induction of anergy by staphylococcal enterotoxin B, also in vivo. Although it is possible that the requirements for anergy in vivo differ from those in vitro, one must also interpret in vivo results carefully due to the increased complexity of in vivo systems. Injection of anti-CTLA-4 Ab may alter the basal responses of T cells other than those being assayed. Unimmunized CTLA-4-deficient mice develop a severe lymphoproliferative disease (49, 50), indicating that CTLA-4 regulates immune responses to environmental and self-Ags. An increase in IL-2 levels due to an enhancement of general T cell activity could prevent or reduce anergy induction (52, 53), independent of any cell-autonomous role for CTLA-4. Consistent with our in vitro results, a recent study found that blockade of CTLA-4 did not have any effect on anergy induction in vivo in a nasal tolerance model (48).

Earlier models of anergy have generally proposed that TCR/CD3 ligation leads to both positive and negative signals in T cells. The decision between activation and anergy would depend on the balance of those signals, with costimulatory pathways tipping the balance from anergy to activation. Kaufman et al. (54) have formulated such a model in mathematical terms, predicting anergy vs activation based on the kinetics of ligand binding and signal transduction. Although this model does not exclude the possible contributions of inhibitory receptors such as CTLA-4, only Ag receptor and IL-2 signaling are required. The model predicts that anergy will follow an activation phase if dissociation of the activating ligand is slow, resulting in a prolonged signal, and this is consistent with our results using anti-CD3 mAb.

An important consideration in trying to build models to understand anergy induction is that the phenomena being studied as anergy are, in fact, a collection of responses to tolerizing stimuli, with different requirements and mechanisms. For example, the ability of anergized cells to differentiate into effector cells or to produce cytokines other than IL-2 (particularly IL-4, IL-10, and IFN-{gamma}) depends on the anergy induction protocol used, as does the ability of CD28 costimulation and exogenous IL-2 to prevent anergy. Thus, CTLA-4 may be important for some pathways to anergy, but is not a universal trigger. Analysis of anergy induction is further complicated by the observation that T cells exposed to various tolerizing conditions can develop into regulatory cells able to suppress the responses of nontolerized cells (55, 56, 57, 58, 59). One mechanism of suppression, observed after injection of bacterial superantigen, involves the production of TGF-ß (59). Induction of TGF-ß secretion is also a result of CTLA-4 signaling (60), suggesting that some apparent effects of CTLA-4 on anergy may, in fact, represent contributions to suppressive mechanisms.

There are considerable data to support a role for CTLA-4 in the down-regulation of immune responses, and a number of strategies to restore or enhance in vivo immune responses by inhibiting CTLA-4 signal transduction have been proposed (61, 62). However, our findings indicate that T cell anergy can be established in the absence of CTLA-4 function, and that studies to establish or reverse Ag-specific anergy should not focus exclusively on CTLA-4. Continued characterization of alternate mechanisms for anergy induction using either the TCR or other T cell-specific receptors is warranted.


   Acknowledgments
 
We thank Thomas Gajewski for providing mice and reagents, Pat Fields and Francesca Fallarino for assistance with anergy induction protocols, Jeffrey Rathmell for assistance with T cell purification, and members of the Thompson laboratory for helpful discussions and critical reading of this manuscript.


   Footnotes
 
1 This work was supported by National Institutes of Health Grants P01DK49799 and 5P01AI35294. Back

2 Address correspondence and reprint requests to Dr. Craig B. Thompson, Abramson Family Cancer Research Institute, University of Pennsylvania, BRB II/III Room 450, 421 Curie Boulevard, Philadelphia, PA 19104-6160. Back

3 Abbreviations used in this paper: RAG, recombination-activating gene; Tg, transgenic. Back

Received for publication October 21, 1999. Accepted for publication January 6, 2000.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Thompson, C. B., T. Lindsten, J. A. Ledbetter, S. L. Kunkel, H. A. Young, S. G. Emerson, J. M. Leiden, C. H. June. 1989. CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. Proc. Natl. Acad. Sci. USA 86:1333.[Abstract/Free Full Text]
  2. Linsley, P. S., W. Brady, L. Grosmaire, A. Aruffo, N. K. Damle, J. A. Ledbetter. 1991. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J. Exp. Med. 173:721.[Abstract/Free Full Text]
  3. Harding, F. A., J. G. McArthur, J. A. Gross, D. H. Raulet, J. P. Allison. 1992. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 356:607.[Medline]
  4. Bierer, B. E., J. Barbosa, S. Herrmann, S. J. Burakoff. 1988. Interaction of CD2 with its ligand, LFA-3, in human T cell proliferation. J. Immunol. 140:3358.[Abstract]
  5. Altmann, D. M., N. Hogg, J. Trowsdale, D. Wilkinson. 1989. Cotransfection of ICAM-1 and HLA-DR reconstitutes human antigen-presenting cell function in mouse L cells. Nature 338:512.[Medline]
  6. Kuhlman, P., V. T. Moy, B. A. Lollo, A. A. Brian. 1991. The accessory function of murine intercellular adhesion molecule-1 in T lymphocyte activation: contributions of adhesion and co-activation. J. Immunol. 146:1773.[Abstract]
  7. Van Seventer, G. A., Y. Shimizu, K. J. Horgan, S. Shaw. 1990. The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T cell receptor-mediated activation of resting T cells. J. Immunol. 144:4579.[Abstract]
  8. Kobata, T., K. Agematsu, J. Kameoka, S. F. Schlossman, C. Morimoto. 1994. CD27 is a signal-transducing molecule involved in CD45RA+ naive T cell costimulation. J. Immunol. 153:5422.[Abstract]
  9. Jenkins, M. K., R. H. Schwartz. 1987. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J. Exp. Med. 165:302.[Abstract/Free Full Text]
  10. Jenkins, M. K., C. A. Chen, G. Jung, D. L. Mueller, R. H. Schwartz. 1990. Inhibition of antigen-specific proliferation of type 1 murine T cell clones after stimulation with immobilized anti-CD3 monoclonal antibody. J. Immunol. 144:16.[Abstract]
  11. Quill, H., R. H. Schwartz. 1987. Stimulation of normal inducer T cell clones with antigen presented by purified Ia molecules in planar lipid membranes: specific induction of a long-lived state of proliferative nonresponsiveness. J. Immunol. 138:3704.[Abstract]
  12. DeSilva, D. R., W. S. Feeser, E. J. Tancula, P. A. Scherle. 1996. Anergic T cells are defective in both Jun NH2-terminal kinase and mitogen-activated protein kinase signaling pathways. J. Exp. Med. 183:2017.[Abstract/Free Full Text]
  13. Li, W., C. D. Whaley, A. Mondino, D. L. Mueller. 1996. Blocked signal transduction to the ERK and JNK protein kinases in anergic CD4+ T cells. Science 271:1272.[Abstract]
  14. Fields, P. E., T. F. Gajewski, F. W. Fitch. 1996. Blocked Ras activation in anergic CD4+ T cells. Science 271:1276.[Abstract]
  15. Gajewski, T. F., D. Qian, P. Fields, F. W. Fitch. 1994. Anergic T-lymphocyte clones have altered inositol phosphate, calcium, and tyrosine kinase signaling pathways. Proc. Natl. Acad. Sci. USA 91:38.[Abstract/Free Full Text]
  16. Boussiotis, V. A., G. J. Freeman, A. Berezovskaya, D. L. Barber, L. M. Nadler. 1997. Maintenance of human T cell anergy: blocking of IL-2 gene transcription by activated Rap1. Science 278:124.[Abstract/Free Full Text]
  17. Kang, S. M., B. Beverly, A. C. Tran, K. Brorson, R. H. Schwartz, M. J. Lenardo. 1992. Transactivation by AP-1 is a molecular target of T cell clonal anergy. Science 257:1134.[Abstract/Free Full Text]
  18. Sundstedt, A., M. Dohlsten. 1998. In vivo anergized CD4+ T cells have defective expression and function of the activating protein-1 transcription factor. J. Immunol. 161:5930.[Abstract/Free Full Text]
  19. Mondino, A., C. D. Whaley, D. R. DeSilva, W. Li, M. K. Jenkins, D. L. Mueller. 1996. Defective transcription of the IL-2 gene is associated with impaired expression of c-Fos, FosB, and JunB in anergic T helper 1 cells. J. Immunol. 157:2048.[Abstract]
  20. Perez, V. L., L. Van Parijs, A. Biuckians, X. X. Zheng, T. B. Strom, A. K. Abbas. 1997. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity 6:411.[Medline]
  21. Walunas, T. L., J. A. Bluestone. 1998. CTLA-4 regulates tolerance induction and T cell differentiation in vivo. J. Immunol. 160:3855.[Abstract/Free Full Text]
  22. Chai, J. G., R. I. Lechler. 1997. Immobilized anti-CD3 mAb induces anergy in murine naive and memory CD4+ T cells in vitro. Int. Immunol. 9:935.[Abstract/Free Full Text]
  23. Dubois, P. M., M. Pihlgren, M. Tomkowiak, M. Van Mechelen, J. Marvel. 1998. Tolerant CD8 T cells induced by multiple injections of peptide antigen show impaired TCR signaling and altered proliferative responses in vitro and in vivo. J. Immunol. 161:5260.[Abstract/Free Full Text]
  24. Hayashi, R. J., D. Y. Loh, O. Kanagawa, F. Wang. 1998. Differences between responses of naive and activated T cells to anergy induction. J. Immunol. 160:33.[Abstract/Free Full Text]
  25. Walunas, T. L., D. J. Lenschow, C. Y. Bakker, P. S. Linsley, G. J. Freeman, J. M. Green, C. B. Thompson, J. A. Bluestone. 1994. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1:405.[Medline]
  26. Krummel, M. F., J. P. Allison. 1995. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 182:459.[Abstract/Free Full Text]
  27. Calvo, C. R., D. Amsen, A. M. Kruisbeek. 1997. Cytotoxic T lymphocyte antigen 4 (CTLA-4) interferes with extracellular signal-regulated kinase (ERK) and Jun NH2-terminal kinase (JNK) activation, but does not affect phosphorylation of T cell receptor {zeta} and ZAP70. J. Exp. Med. 186:1645.[Abstract/Free Full Text]
  28. Lee, K. M., E. Chuang, M. Griffin, R. Khattri, D. K. Hong, W. Zhang, D. Straus, L. E. Samelson, C. B. Thompson, J. A. Bluestone. 1998. Molecular basis of T cell inactivation by CTLA-4. Science 282:2263.[Abstract/Free Full Text]
  29. Fraser, J. H., M. Rincon, K. D. McCoy, G. Le Gros. 1999. CTLA4 ligation attenuates AP-1, NFAT and NF-{kappa}B activity in activated T cells. Eur. J. Immunol. 29:838.[Medline]
  30. Samoilova, E. B., J. L. Horton, H. Zhang, S. J. Khoury, H. L. Weiner, Y. Chen. 1998. CTLA-4 is required for the induction of high dose oral tolerance. Int. Immunol. 10:491.[Abstract/Free Full Text]
  31. Issazadeh, S., M. Zhang, M. H. Sayegh, S. J. Khoury. 1999. Acquired thymic tolerance: role of CTLA4 in the initiation and maintenance of tolerance in a clinically relevant autoimmune disease model. J. Immunol. 162:761.[Abstract/Free Full Text]
  32. Judge, T. A., Z. Wu, X. G. Zheng, A. H. Sharpe, M. H. Sayegh, L. A. Turka. 1999. The role of CD80, CD86, and CTLA4 in alloimmune responses and the induction of long-term allograft survival. J. Immunol. 162:1947.[Abstract/Free Full Text]
  33. Chen, C., N. Nabavi. 1994. In vitro induction of T cell anergy by blocking B7 and early T cell costimulatory molecule ETC-1/B7-2. Immunity 1:147.[Medline]
  34. Yi-qun, Z., K. Lorre, M. de Boer, J. L. Ceuppens. 1997. B7-blocking agents, alone or in combination with cyclosporin A, induce antigen-specific anergy of human memory T cells. J. Immunol. 158:4734.[Abstract]
  35. Van Gool, S. W., M. de Boer, J. L. Ceuppens. 1994. The combination of anti-B7 monoclonal antibody and cyclosporin A induces alloantigen-specific anergy during a primary mixed lymphocyte reaction. J. Exp. Med. 179:715.[Abstract/Free Full Text]
  36. Tan, P., C. Anasetti, J. A. Hansen, J. Melrose, M. Brunvand, J. Bradshaw, J. A. Ledbetter, P. S. Linsley. 1993. Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. J. Exp. Med. 177:165.[Abstract/Free Full Text]
  37. Chai, J. G., I. Bartok, D. Scott, J. Dyson, R. Lechler. 1998. T:T antigen presentation by activated murine CD8+ T cells induces anergy and apoptosis. J. Immunol. 160:3655.[Abstract/Free Full Text]
  38. McIntosh, K. R., P. S. Linsley, D. B. Drachman. 1995. Immunosuppression and induction of anergy by CTLA4Ig in vitro: effects on cellular and antibody responses of lymphocytes from rats with experimental autoimmune myasthenia gravis. Cell. Immunol. 166:103.[Medline]
  39. Chao, D. T., G. P. Linette, L. H. Boise, L. S. White, C. B. Thompson, S. J. Korsmeyer. 1995. Bcl-xL and Bcl-2 repress a common pathway of cell death. J. Exp. Med. 182:821.[Abstract/Free Full Text]
  40. Mamalaki, C., J. Elliott, T. Norton, N. Yannoutsos, A. R. Townsend, P. Chandler, E. Simpson, D. Kioussis. 1993. Positive and negative selection in transgenic mice expressing a T-cell receptor specific for influenza nucleoprotein and endogenous superantigen. Dev. Immunol. 3:159.[Medline]
  41. Sha, W. C., C. A. Nelson, R. D. Newberry, D. M. Kranz, J. H. Russell, D. Y. Loh. 1988. Selective expression of an antigen receptor on CD8-bearing T lymphocytes in transgenic mice. Nature 335:271.[Medline]
  42. Murphy, K. M., A. B. Heimberger, D. Y. Loh. 1990. Induction by antigen of intrathymic apoptosis of CD4+ CD8+ TCRlo thymocytes in vivo. Science 250:1720.[Abstract/Free Full Text]
  43. Gilbert, K. M., D. N. Ernst, M. V. Hobbs, W. O. Weigle. 1992. Effects of tolerance induction on early cell cycle progression by Th1 clones. Cell. Immunol. 141:362.[Medline]
  44. Gilbert, K. M., W. O. Weigle. 1993. Th1 cell anergy and blockade in G1a phase of the cell cycle. J. Immunol. 151:1245.[Abstract]
  45. Powell, J. D., C. G. Lerner, R. H. Schwartz. 1999. Inhibition of cell cycle progression by rapamycin induces T cell clonal anergy even in the presence of costimulation. J. Immunol. 162:2775.[Abstract/Free Full Text]
  46. Lanoue, A., C. Bona, H. von Boehmer, A. Sarukhan. 1997. Conditions that induce tolerance in mature CD4+ T cells. J. Exp. Med. 185:405.[Abstract/Free Full Text]
  47. Sun, J., B. Dirden-Kramer, K. Ito, P. B. Ernst, N. Van Houten. 1999. Antigen-specific T cell activation and proliferation during oral tolerance induction. J. Immunol. 162:5868.[Abstract/Free Full Text]
  48. Tsitoura, D., R. DeKruyff, J. Lamb, D. Umetsu. 1999. Intranasal exposure to protein antigen induces immunological tolerance mediated by functionally disabled CD4+ T cells. J. Immunol. 163:2592.[Abstract/Free Full Text]
  49. Tivol, E. A., F. Borriello, A. N. Schweitzer, W. P. Lynch, J. A. Bluestone, A. H. Sharpe. 1995. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3:541.[Medline]
  50. Waterhouse, P., J. M. Penninger, E. Timms, A. Wakeham, A. Shahinian, K. P. Lee, C. B. Thompson, H. Griesser, T. W. Mak. 1995. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270:985.[Abstract/Free Full Text]
  51. Lin, H., J. C. Rathmell, G. S. Gray, C. B. Thompson, J. M. Leiden, M. L. Alegre. 1998. Cytotoxic T lymphocyte antigen 4 (CTLA4) blockade accelerates the acute rejection of cardiac allografts in CD28-deficient mice: CTLA4 can function independently of CD28. J. Exp. Med. 188:199.[Abstract/Free Full Text]
  52. DeSilva, D. R., K. B. Urdahl, M. K. Jenkins. 1991. Clonal anergy is induced in vitro by T cell receptor occupancy in the absence of proliferation. J. Immunol. 147:3261.[Abstract]
  53. Madrenas, J., R. H. Schwartz, R. N. Germain. 1996. Interleukin 2 production, not the pattern of early T-cell antigen receptor-dependent tyrosine phosphorylation, controls anergy induction by both agonists and partial agonists. Proc. Natl. Acad. Sci. USA 93:9736.[Abstract/Free Full Text]
  54. Kaufman, M., F. Andris, O. Leo. 1999. A logical analysis of T cell activation and anergy. Proc. Natl. Acad. Sci. USA 96:3894.[Abstract/Free Full Text]
  55. Lombardi, G., S. Sidhu, R. Batchelor, R. Lechler. 1994. Anergic T cells as suppressor cells in vitro. Science 264:1587.[Abstract/Free Full Text]
  56. Takahashi, T., Y. Kuniyasu, M. Toda, N. Sakaguchi, M. Itoh, M. Iwata, J. Shimizu, S. Sakaguchi. 1998. Immunologic self-tolerance maintained by CD25+ CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int. Immunol. 10:1969.[Abstract/Free Full Text]
  57. Thornton, A. M., E. M. Shevach. 1998. CD4+ CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J. Exp. Med. 188:287.[Abstract/Free Full Text]
  58. Taams, L. S., A. J. van Rensen, M. C. Poelen, C. A. van Els, A. C. Besseling, J. P. Wagenaar, W. van Eden, M. H. Wauben. 1998. Anergic T cells actively suppress T cell responses via the antigen- presenting cell. Eur. J. Immunol. 28:2902.[Medline]
  59. Miller, C., J. A. Ragheb, R. H. Schwartz. 1999. Anergy and cytokine-mediated suppression as distinct superantigen-induced tolerance mechanisms in vivo. J. Exp. Med. 190:53.[Abstract/Free Full Text]
  60. Chen, W., W. Jin, S. M. Wahl. 1998. Engagement of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) induces transforming growth factor ß (TGF-ß) production by murine CD4+ T cells. J. Exp. Med. 188:1849.[Abstract/Free Full Text]
  61. Leach, D. R., M. F. Krummel, J. P. Allison. 1996. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271:1734.[Abstract]
  62. Hurwitz, A. A., T. F. Y. Yu, D. R. Leach, J. P. Allison. 1998. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc. Natl. Acad. Sci. USA 95:10067.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Exp. Biol. Med.Home page
K. Kolegraff, P. Bostik, and A. A. Ansari
Characterization and role of lentivirus-associated host proteins.
Experimental Biology and Medicine, March 1, 2006; 231(3): 252 - 263.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
P. R. O. Salvalaggio, G. Camirand, C. E. Ariyan, S. Deng, L. Rogozinski, G. P. Basadonna, and D. M. Rothstein
Antigen Exposure during Enhanced CTLA-4 Expression Promotes Allograft Tolerance In Vivo
J. Immunol., February 15, 2006; 176(4): 2292 - 2298.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
S. Mukherjee, A. Ahmed, and D. Nandi
CTLA4-CD80/CD86 interactions on primary mouse CD4+ T cells integrate signal-strength information to modulate activation with Concanavalin A
J. Leukoc. Biol., July 1, 2005; 78(1): 144 - 157.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. Inobe and R. H. Schwartz
CTLA-4 Engagement Acts as a Brake on CD4+ T Cell Proliferation and Cytokine Production but Is Not Required for Tuning T Cell Reactivity in Adaptive Tolerance
J. Immunol., December 15, 2004; 173(12): 7239 - 7248.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
G. Borkow and Z. Bentwich
Chronic Immune Activation Associated with Chronic Helminthic and Human Immunodeficiency Virus Infections: Role of Hyporesponsiveness and Anergy
Clin. Microbiol. Rev., October 1, 2004; 17(4): 1012 - 1030.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
F. Andris, S. Denanglaire, F. de Mattia, J. Urbain, and O. Leo
Naive T Cells Are Resistant to Anergy Induction by Anti-CD3 Antibodies
J. Immunol., September 1, 2004; 173(5): 3201 - 3208.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
T. N. Eagar, D. M. Turley, J. Padilla, N. J. Karandikar, L. Tan, J. A. Bluestone, and S. D. Miller
CTLA-4 Regulates Expansion and Differentiation of Th1 Cells Following Induction of Peripheral T Cell Tolerance
J. Immunol., June 15, 2004; 172(12): 7442 - 7450.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
S. Mukherjee, P. K. Maiti, and D. Nandi
Role of CD80, CD86, and CTLA4 on mouse CD4+ T lymphocytes in enhancing cell-cycle progression and survival after activation with PMA and ionomycin
J. Leukoc. Biol., November 1, 2002; 72(5): 921 - 931.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y. L. Wang, K. A. Frauwirth, S. M. Rangwala, M. A. Lazar, and C. B. Thompson
Thiazolidinedione Activation of Peroxisome Proliferator-activated Receptor gamma Can Enhance Mitochondrial Potential and Promote Cell Survival
J. Biol. Chem., August 23, 2002; 277(35): 31781 - 31788.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
R. E. Miller, J. Jones, T. Le, J. Whitmore, N. Boiani, B. Gliniak, and D. H. Lynch
4-1BB-Specific Monoclonal Antibody Promotes the Generation of Tumor-Specific Immune Responses by Direct Activation of CD8 T Cells in a CD40-Dependent Manner
J. Immunol., August 15, 2002; 169(4): 1792 - 1800.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
E. A. Tivol and J. Gorski
Re-establishing Peripheral Tolerance in the Absence of CTLA-4: Complementation by Wild-Type T Cells Points to an Indirect Role for CTLA-4
J. Immunol., August 15, 2002; 169(4): 1852 - 1858.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
T. L. Vanasek, A. Khoruts, T. Zell, and D. L. Mueller
Antagonistic Roles for CTLA-4 and the Mammalian Target of Rapamycin in the Regulation of Clonal Anergy: Enhanced Cell Cycle Progression Promotes Recall Antigen Responsiveness
J. Immunol., November 15, 2001; 167(10): 5636 - 5644.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K. A. Frauwirth, M.-L. Alegre, and C. B. Thompson
CTLA-4 Is Not Required for Induction of CD8+ T Cell Anergy In Vivo
J. Immunol., November 1, 2001; 167(9): 4936 - 4941.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. Ermann, V. Szanya, G. S. Ford, V. Paragas, C. G. Fathman, and K. Lejon
CD4+CD25+ T Cells Facilitate the Induction of T Cell Anergy
J. Immunol., October 15, 2001; 167(8): 4271 - 4275.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M.-N. Avice, M. Rubio, M. Sergerie, G. Delespesse, and M. Sarfati
Role of CD47 in the Induction of Human Naive T Cell Anergy
J. Immunol., September 1, 2001; 167(5): 2459 - 2468.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
E. Prager, G. Staffler, O. Majdic, M. D. Saemann, S. Godar, G. J. Zlabinger, and H. Stockinger
Induction of Hyporesponsiveness and Impaired T Lymphocyte Activation by the CD31 Receptor:Ligand Pathway in T Cells
J. Immunol., February 15, 2001; 166(4): 2364 - 2371.
[Abstract] [Full Text] [PDF]